Medindia

X

New 'Reaxys' Solution Improves Workflow Quality and Efficiency for Chemists

Tuesday, January 27, 2009 General News J E 4
Advertisement
FRANKFURT, Germany, January 26

- Elsevier's New Web-Based Solution Combines Content From the TrustedCrossFire Databases in a Highly Intuitive and Easy to use Interface With NewFeatures and Functionality

Elsevier, the leading publisher of scientific, medical and technicalproducts and services, today introduced Reaxys, a new workflow solution forsynthetic chemists. Reaxys is based on data from Elsevier's industry leadingchemistry databases (CrossFire Beilstein, CrossFire Gmelin and PatentChemistry Database) now merged together to provide harmonized content,additional functionalities and a redesigned interface to help improve R&Defficiency. Reaxys also contains new unique features including a synthesisplanner and advanced results handling to help scientists gather relevantinformation more efficiently.

"Scientists, both in academia and industry, are under increasing pressureto deliver more and better results in a shorter time and make researchdecisions faster," said Mark van Mierle, managing director for ElsevierInformation Systems. "Reaxys now gives them a tool to quickly create anoverview of the of synthesis design options available for their work,research and quickly identify and select the most appropriate. By integratingchemical reaction and substance data from trusted sources with a synthesisdesign process, customers can accelerate early phase discovery."

Reaxys has been developed with input and advice from development partnersfrom corporate and academic research institutions around the world. Inaddition, the web interface has been designed by experts in human-computerinteraction. The look and feel has been streamlined to make searching easierand provide a clear visualization of the results.

The result is a solution that goes beyond retrieving data. Search resultsreflect how chemists think and work, helping their workflow move seamlesslyfrom initial search, recognition of possible starting materials and theirproperties and through planning a strategy for the synthesis of a newcompound to proposing a detailed synthetic route. Most compounds in Reaxyscan be identified by their CAS Registry Numbers(R).

Migrating from Crossfire to Reaxys

Reaxys is available today and existing CrossFire customers may use Reaxysin parallel for an interim period. Elsevier offers full training and helpdesksupport for new customers as well as guidance for the migration fromCrossFire to the new platform. For the time being all CrossFire products aswell as the Commander interface will be fully supported.

Select customers have been evaluating Reaxys throughout its developmentand have provided positive feedback. Elsevier will continue to engage withthe chemistry community in future product development. For more information,visit http://www.info.reaxys.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical andmedical information products and services. Working in partnership with theglobal science and health communities, Elsevier's 7,000 employees in over 70offices worldwide publish more than 2,000 journals and 1,900 new books peryear, in addition to offering a suite of innovative electronic products, suchas ScienceDirect (http://www.sciencedirect.com/), MD Consult(http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered inAmsterdam, The Netherlands and has offices worldwide. Elsevier is part ofReed Elsevier Group plc (http://www.reedelsevier.com/), a world-leadingpublisher and information provider. Operating in the science and medical,legal, education and business-to-business sectors, Reed Elsevier provideshigh-quality and flexible information solutions to users, with increasingemphasis on the Internet as a means of delivery. Reed Elsevier's tickersymbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK andENL (New York Stock Exchange).

Reaxys(TM) and CrossFire Beilstein are owned and protected by ElsevierProperties SA and used under license.

More about the addition of CAS Registry Numbers(R) can be found in arecent agreement between CAS (Chemical Abstract Service) and Elsevier:http://www.info.reaxys.com/press_room.Features include: - Workflow and decision making support for synthesis design and planning, e.g. by comparing alternative synthesis routes and selecting the most relevant paths; - Quick access to key data by displaying results in a unique tabulated overview of the most important information; - Convenient and flexible output of data in most common formats.

SOURCE Elsevier
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Hospice Care Remains a Misunderstood and Underutil...
S
Lost Your Job in Retail? Why Not Operate Your Own ...